The purpose of the study is to compare the efficacy and safety of benralizumab versus placebo and to compare benralizumab dosing regimens during extension period.
The aim of this study is to investigate the use of benralizumab as treatment for patients with moderate to severe atopic dermatitis (AD) who remain symptomatic despite treatment with topical medications. It is proposed that benralizumab will deplete eosinophils from affected skin, improve symptoms of AD, and improve AD-related quality of life. This Phase 2 study is designed to compare the efficacy of treatment with benralizumab versus placebo and compare benralizumab maintenance dosing regimens in the extension period.
| Condition | Dermatitis, Dermatite Atopique, Atopic Dermatitis, Eczema (Atopic Dermatitis), ATOPIC DERMATITIS, Dermatitis, Atopic, Eczema (Atopic Dermatitis - Pediatric), Hand Dermatitis, Eczéma (Dermatite Atopique), Eczema |
|---|---|
| Treatment | benralizumab, Placebo / Benralizumab |
| Clinical Study Identifier | NCT04605094 |
| Sponsor | AstraZeneca |
| Last Modified on | 2 June 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.